Microenvironment engineering of osteoblastic bone metastases reveals osteomimicry of patient-derived prostate cancer xenografts
- PMID: 31400612
- DOI: 10.1016/j.biomaterials.2019.119402
Microenvironment engineering of osteoblastic bone metastases reveals osteomimicry of patient-derived prostate cancer xenografts
Abstract
Representative in vitro models that mimic the native bone tumor microenvironment are warranted to support the development of more successful treatments for bone metastases. Here, we have developed a primary cell 3D model consisting of a human osteoblast-derived tissue-engineered construct (hOTEC) indirectly co-cultured with patient-derived prostate cancer xenografts (PDXs), in order to study molecular interactions in a patient-derived microenvironment context. The engineered biomimetic microenvironment had high mineralization and embedded osteocytes, and supported a high degree of cancer cell osteomimicry at the gene, protein and mineralization levels when co-cultured with prostate cancer PDXs from a lymph node metastasis (LuCaP35) and bone metastasis (BM18) from patients with primary prostate cancer. This fully patient-derived model is a promising tool for the assessment of new molecular mechanisms and as a personalized pre-clinical platform for therapy testing for patients with prostate cancer bone metastases.
Keywords: Bone metastasis; Cancer model; Osteocyte; Osteomimicry; Patient-derived xenograft; Prostate cancer.
Copyright © 2019 Elsevier Ltd. All rights reserved.
Similar articles
-
Canine prostatic cancer cell line (LuMa) with osteoblastic bone metastasis.Prostate. 2020 Jun;80(9):698-714. doi: 10.1002/pros.23983. Epub 2020 Apr 29. Prostate. 2020. PMID: 32348616 Free PMC article.
-
Mineralized human primary osteoblast matrices as a model system to analyse interactions of prostate cancer cells with the bone microenvironment.Biomaterials. 2010 Nov;31(31):7928-36. doi: 10.1016/j.biomaterials.2010.06.055. Epub 2010 Aug 5. Biomaterials. 2010. PMID: 20688384
-
A 3D in vitro model of patient-derived prostate cancer xenograft for controlled interrogation of in vivo tumor-stromal interactions.Biomaterials. 2016 Jan;77:164-72. doi: 10.1016/j.biomaterials.2015.10.059. Epub 2015 Nov 9. Biomaterials. 2016. PMID: 26599623 Free PMC article.
-
Emerging Players in Prostate Cancer-Bone Niche Communication.Trends Cancer. 2021 Feb;7(2):112-121. doi: 10.1016/j.trecan.2020.09.006. Epub 2020 Oct 24. Trends Cancer. 2021. PMID: 33274720 Review.
-
Molecular insights into prostate cancer progression: the missing link of tumor microenvironment.J Urol. 2005 Jan;173(1):10-20. doi: 10.1097/01.ju.0000141582.15218.10. J Urol. 2005. PMID: 15592017 Review.
Cited by
-
Bioprinted research models of urological malignancy.Exploration (Beijing). 2024 Feb 20;4(4):20230126. doi: 10.1002/EXP.20230126. eCollection 2024 Aug. Exploration (Beijing). 2024. PMID: 39175884 Free PMC article. Review.
-
Poly-ε-Caprolactone/Fibrin-Alginate Scaffold: A New Pro-Angiogenic Composite Biomaterial for the Treatment of Bone Defects.Polymers (Basel). 2021 Oct 2;13(19):3399. doi: 10.3390/polym13193399. Polymers (Basel). 2021. PMID: 34641215 Free PMC article.
-
Recent advances in 3D bioprinted tumor models for personalized medicine.Transl Oncol. 2023 Nov;37:101750. doi: 10.1016/j.tranon.2023.101750. Epub 2023 Aug 10. Transl Oncol. 2023. PMID: 37572498 Free PMC article.
-
In vitro engineering of a bone metastases model allows for study of the effects of antiandrogen therapies in advanced prostate cancer.Sci Adv. 2021 Jun 30;7(27):eabg2564. doi: 10.1126/sciadv.abg2564. Print 2021 Jun. Sci Adv. 2021. PMID: 34193425 Free PMC article.
-
Experimental in vitro, ex vivo and in vivo models in prostate cancer research.Nat Rev Urol. 2023 Mar;20(3):158-178. doi: 10.1038/s41585-022-00677-z. Epub 2022 Nov 30. Nat Rev Urol. 2023. PMID: 36451039 Review.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical